Yusuke Chihara

5PUBLICATIONS
30CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|Sep 20, 2024
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.

Makoto Hibino, Yoshinori Imamura, Rai Shimoyama

|Jan 19, 2024
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.

Yuki Katayama, Tadaaki Yamada, Ryo Sawada

|Apr 13, 2023
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Keiko Tanimura, Junji Uchino, Hideharu Kimura

|Oct 01, 2022
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.

Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto

Pageof 1

Frequent Collaborators

2 joint publications

Tadaaki Yamada

2 joint publications

Makoto Hibino

2 joint publications

Tomoya Fukui

1 joint publications

Yuki Katayama